China Reporting from Chinese language media outlet Yaozh, based on recently issued annual financial reporting, shows the leading R&D spenders among the (predominantly mainland Chinese) biotech companies listed on the Hong Kong Stock Exchange (HKEX). Local heavyweight Beigene invested almost three times as much on R&D last year as its nearest…

China The Chinese pharma market grew by eight percent from 2016 to 2018, slowed to four percent between 2018 and 2022 in part thanks to the introduction of volume-based procurement (VBP), and looks set to return to a healthier seven percent compound annual growth rate (CAGR) up to 2025 driven by…

China The top 10 Chinese pharma companies for 2022, ranked by sales value and based on data from the latest Forbes Global 2000 ranking. Big conglomerates like Sinopharm, Shanghai Pharmaceuticals, and Jointown dominate the list, while other national champions in the midst of expanding their innovation efforts like Jiangsu Hengrui and…

China The latest reporting on China biopharma dealmaking from MSQ Ventures, including the Top 10 biotech in-licensing deals in H1 2021, the Top 5 out-licensing deals, and Top 10 IPOs.   Made with Visme Infographic Maker Made with Visme Infographic Maker Made with Visme Infographic Maker

China The Top 10 Chinese pharma companies for 2020 ranked by overall revenues. Taken from Fortune magazine’s 2020 list of the 500 biggest companies in China, this up-to-date list shows Shanghai Pharma in pole position, followed by China Resources Pharmaceutical, and Guangzhou Baiyunshan.     Made with Visme Infographic Maker

China The Chinese NMPA’s drug approval list for 2020 includes a surge in approvals for locally developed drugs. A total of 46 new drugs were approved in 2020 (less than the 53 approved in 2019), including 28 chemical drugs and 18 biological products. Read more analysis from Xu Wang of Novo…

China While many parts of the world ground to a halt as they tried to deal with the global pandemic, China had more or less brought the situation under control by June, and the healthcare deals engine just kept on churning. MSQ Ventures recently published its 2020 China Biopharma Global Transactions…

China Biosimilars are a relatively recent development in the pharmaceutical industry, meaning market penetration is still fairly low, even in many developed markets, much less emerging markets. Prior to 2019, not a single biosimilar had been approved in China. However, a McKinsey analysis found that biosimilars could account for a growing…

Rankings These ten Chinese pharma companies ranked by 2018 revenues, each brought in more than a billion US dollars. Sinopharm comes out on top with revenues of USD 48.5 billion. Made with Visme Infographic Maker

China China has expanded to be the second largest pharmaceutical market globally with USD 137 billion in total spending in 2018, but growth has slowed from a 19% CAGR in 2008–2013 to an 8% CAGR in 2013–2018 and is expected to continue to decline to 3-6% through 2023, as the below…

China The Greater Bay Area (several cities in Guangdong Province in mainland China along with Hong Kong and Macau) is a major Chinese government scheme to link the entire region into an integrated economic and business hub . The Greater Bay Area, taken as a whole, dwarfs the world’s other major…

Pharma India leads the way in terms of the sheer volume of US FDA-approved manufacturing plants with over 100, compared to only 28 in China. In terms of the global competitiveness of Brazil, Russia, India, China and South Africa (BRICS), China remained out in front between 2012 and 2015, with India…